Leanne McCulloch

776 total citations
16 papers, 459 citations indexed

About

Leanne McCulloch is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Leanne McCulloch has authored 16 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Oncology and 8 papers in Hematology. Recurrent topics in Leanne McCulloch's work include Multiple Myeloma Research and Treatments (7 papers), Advanced Breast Cancer Therapies (5 papers) and Gastric Cancer Management and Outcomes (5 papers). Leanne McCulloch is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Advanced Breast Cancer Therapies (5 papers) and Gastric Cancer Management and Outcomes (5 papers). Leanne McCulloch collaborates with scholars based in United States, Canada and Australia. Leanne McCulloch's co-authors include Sagar Lonial, Rubén Niesvizky, Ravi Vij, Ashraf Badros, Sundar Jagannath, Kanya Rajangam, Alvin Wong, David Siegel, Thomas G Martin and R. Donald Harvey and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Leanne McCulloch

16 papers receiving 437 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leanne McCulloch United States 8 261 233 202 73 67 16 459
Feras Abu Saadeh Ireland 11 71 0.3× 115 0.5× 73 0.4× 46 0.6× 100 1.5× 41 483
Serguei A. Castañeda United States 10 137 0.5× 130 0.6× 52 0.3× 39 0.5× 15 0.2× 22 400
Chet Bohac United States 10 51 0.2× 54 0.2× 223 1.1× 109 1.5× 26 0.4× 21 340
Sung-Nam Lim South Korea 12 119 0.5× 183 0.8× 140 0.7× 152 2.1× 8 0.1× 31 455
Erika Šoba Slovenia 11 87 0.3× 67 0.3× 133 0.7× 118 1.6× 28 0.4× 16 396
A. Franke Germany 11 135 0.5× 58 0.2× 107 0.5× 24 0.3× 31 0.5× 28 362
M. Vassilomanolakis Greece 13 41 0.2× 55 0.2× 213 1.1× 68 0.9× 36 0.5× 16 338
Richard Mansour United States 9 62 0.2× 40 0.2× 152 0.8× 71 1.0× 30 0.4× 56 326
Jodi V. Mones United States 8 103 0.4× 25 0.1× 90 0.4× 41 0.6× 61 0.9× 21 283
Mathias Haenel Germany 11 89 0.3× 64 0.3× 266 1.3× 61 0.8× 16 0.2× 37 509

Countries citing papers authored by Leanne McCulloch

Since Specialization
Citations

This map shows the geographic impact of Leanne McCulloch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leanne McCulloch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leanne McCulloch more than expected).

Fields of papers citing papers by Leanne McCulloch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leanne McCulloch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leanne McCulloch. The network helps show where Leanne McCulloch may publish in the future.

Co-authorship network of co-authors of Leanne McCulloch

This figure shows the co-authorship network connecting the top 25 collaborators of Leanne McCulloch. A scholar is included among the top collaborators of Leanne McCulloch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leanne McCulloch. Leanne McCulloch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
3.
Ruíz‐Borrego, Manuel, Arlene Chan, Gavin Marx, et al.. (2021). Abstract PS13-20: Bringing diarrhea under CONTROL: Dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer. Cancer Research. 81(4_Supplement). PS13–20. 5 indexed citations
4.
5.
Bárcenas, Carlos H., Sara A. Hurvitz, Jack A. Di Palma, et al.. (2019). Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial.. Journal of Clinical Oncology. 37(15_suppl). 548–548. 7 indexed citations
6.
7.
Siegel, David, Thomas G Martin, R. Donald Harvey, et al.. (2013). Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 98(11). 1753–1761. 259 indexed citations
8.
Nooka, Ajay K., Ashraf Badros, Priti Patel, et al.. (2012). Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma. Journal of Clinical Oncology. 30(15_suppl). 8086–8086. 13 indexed citations
9.
Lonial, Sagar, Rubén Niesvizky, Leanne McCulloch, Kanya Rajangam, & Ravi Vij. (2012). Cardiac and Pulmonary Safety Profile of Single-Agent Carfilzomib From Four Phase 2 Studies in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood. 120(21). 4037–4037. 6 indexed citations
10.
Harvey, R. Donald, Sagar Lonial, Priti Patel, et al.. (2012). Summary of treatment-emergent renal events from patients treated with single-agent carfilzomib from four phase II studies in relapsed and/or refractory multiple myeloma.. Journal of Clinical Oncology. 30(15_suppl). e18569–e18569. 2 indexed citations
11.
Singhal, Seema, David S. Siegel, Thomas G. Martin, et al.. (2011). Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. Blood. 118(21). 1876–1876. 32 indexed citations
12.
Singhal, Seema, David S. Siegel, Thomas G. Martin, et al.. (2010). Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM). Blood. 116(21). 1954–1954. 9 indexed citations
13.
Jagannath, Sundar, Ravi Vij, Jonathan L. Kaufman, et al.. (2010). Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM). Blood. 116(21). 1953–1953. 6 indexed citations
14.
Furman, Richard R., Nancy L. Bartlett, Alvin Wong, et al.. (2006). Banoxantrone (AQ4N), a Tissue Targeted Prodrug: Results of a Phase 1 Study in Lymphomas.. Blood. 108(11). 2429–2429. 4 indexed citations
15.
Burbridge, Brent, et al.. (1999). Doppler ultrasonographic examination of the leg veins of patients with Parkinson disease.. PubMed. 24(4). 338–40. 12 indexed citations
16.
Wong, Alvin, Leanne McCulloch, & Augusto Sola. (1992). Treatment of peripheral tissue ischemia with topical nitroglycerin ointment in neonates. The Journal of Pediatrics. 121(6). 980–983. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Feras Abu Saadeh Breakdown of academic impact, for papers by Serguei A. Castañeda Breakdown of academic impact, for papers by Chet Bohac Breakdown of academic impact, for papers by Sung-Nam Lim Breakdown of academic impact, for papers by Erika Šoba Breakdown of academic impact, for papers by A. Franke Breakdown of academic impact, for papers by M. Vassilomanolakis Breakdown of academic impact, for papers by Richard Mansour Breakdown of academic impact, for papers by Jodi V. Mones Breakdown of academic impact, for papers by Mathias Haenel
Rankless by CCL
2026